

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-04-22** | Period of Report: **2024-04-17**
SEC Accession No. [0001193125-24-104896](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Bellevue Life Sciences Acquisition Corp.

CIK: [1840425](#) | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: [001-41390](#) | Film No.: **24861465**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address
10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41390
(Commission
File Number)

84-5052822
(IRS Employer
Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA
(Address of Principal Executive Offices)

98004
(Zip Code)

Registrant's telephone number, including area code (425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right	BLACU	The Nasdaq Stock Market LLC
Common stock, par value \$0.0001 per share	BLAC	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share	BLACW	The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock	BLACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On April 17, 2024, Bellevue Life Sciences Acquisition Corp. (the “*Company*”) issued an unsecured promissory note (the “*Promissory Note*”) in the principal amount of \$50,000 to Bellevue Global Life Sciences Investors LLC (“*BGLSI*”), the sponsor of the Company.

The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) December 31, 2024 or (ii) the date on which the Company consummates an initial business combination (the “*Maturity Date*”). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company’s Amended and Restated Certificate of Incorporation (as subject to extension), BGLSI agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company’s trust account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action.

The foregoing description of the Promissory Note is qualified in its entirety by reference to the full text of the Promissory Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on February 15, 2024, the Company received a letter (the “*Notice*”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“*Nasdaq*”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “*Minimum Public Holders Requirement*”). The Notice stated that the Company had 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement.

On April 1, 2024, the Company submitted to Nasdaq a plan to regain compliance with the Minimum Public Holders Requirement. On April 17, 2024, the Company received a written notice from Nasdaq indicating that the staff of Nasdaq (the “*Staff*”) has determined, based on its review of the Company’s compliance plan, to grant the Company an extension of time to regain compliance with the Minimum Public Holders Requirement. The terms of the extension are as follows: on or before August 13, 2024, the Company must file with Nasdaq documentation from its transfer agent, or independent source, that demonstrates that its common stock has a minimum of 300 public holders. In the event the Company does not satisfy the terms, the Staff will provide written notification that the Company’s securities will be delisted. At that time, the Company may appeal the Staff’s determination to a Listing Qualifications Panel.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
10.1	Promissory Note, dated April 17, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Bellevue Global Life Sciences Investors LLC
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 22, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang

Name: Kuk Hyoun Hwang

Title: Chief Executive Officer

PROMISSORY NOTE

Principal Amount: \$50,000

Dated April 17, 2024

Bellevue Life Sciences Acquisition Corp., a Delaware corporation and blank check company (the “**Maker**”), promises to pay to the order of Bellevue Global Life Sciences Investors LLC or its registered assigns or successors in interest (the “**Payee**”), the principal sum of fifty thousand dollars (\$50,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this promissory note (“**Note**”) shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1. Principal. The principal balance of this Note shall be payable by the Maker on the earlier of: (i) December 31, 2024 or (ii) the date on which Maker consummates an initial business combination (the “**Maturity Date**”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any manager, member, officer, director, employee or stockholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

2. Interest. No interest shall accrue on the unpaid principal balance of this Note.

3. Representations and Warranties. Maker represents and warrants to Payee on the date hereof as follows:

(a) Existence. Maker is a corporation duly incorporated, validly existing and in good standing under the laws of the state of Delaware.

(b) Power and Authority. Maker has the power and authority, and the legal right, to execute and deliver this Note and to perform its obligations hereunder.

(c) Authorization; Execution and Delivery. The execution and delivery of this Note by Maker and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with all applicable laws. The Maker has duly executed and delivered this Note.

(d) No Approvals. No consent or authorization of, filing with, notice to or other act by, or in respect of, any governmental authority is required in order for Maker to execute, deliver, or perform any of its obligations under this Note.

(e) No Violations. The execution and delivery of this Note and the consummation by the Maker of the transactions contemplated hereby do not and will not (a) violate any provision of Maker’s organizational documents; (b) violate any law applicable to the Maker or by which any of its properties or assets may be bound; or (c) constitute a default under any material agreement or contract by which Maker may be bound.

(f) Enforceability. The Note is a valid, legal and binding obligation of Maker, enforceable against Maker in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

4. Events of Default. Each of the following shall constitute an event of default (“**Event of Default**”):

(a) Failure to Make Required Payments. Failure by Maker to pay the outstanding balance due pursuant to this Note within five (5) business days of the date specified in Section 1 above.

(b) Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

(c) Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

5. Remedies.

(a) Upon the occurrence of an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the outstanding balance of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

(b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

6. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

7. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker's liability hereunder.

8. Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be made in writing and delivered (i) personally or sent by first class registered or certified mail, or overnight courier service, to the address most recently provided to such party or such other address as may be designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail

address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

9. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

10. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

11. Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“**Claim**”) in or to any distribution of or from the trust account established in which the proceeds of the initial public offering (the “**IPO**”) conducted by the Maker (including the deferred underwriters discounts and commissions) and the proceeds of the sale of the units issued in a private placement that occurred in connection with the IPO are to be deposited (the “**Trust Account**”), as described in greater detail in the registration statement and prospectus filed with the Securities and Exchange Commission in connection with the IPO (the “**Registration Statement**”), and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever; provided, however, the Payee shall not waive any Claim it may have if the Maker fails to repay the outstanding balance due in connection with this Note pursuant to Section 4(a) hereof. In addition, Payee hereby agrees that the principal balance of this Note will be forgiven if the Maker is unable to consummate an initial business combination on or prior to the time provided in Maker’s Amended and Restated Certificate of Incorporation (as subject to extension), except to the extent of any funds held by Maker outside of the Trust Account.

12. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

13. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

[Signature Page Follows]

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang
Name: Kuk Hyoun Hwang
Title: Chief Executive Officer
Email: [**]

Payee hereby acknowledges and agrees to the foregoing as of the date first written above.

ACKNOWLEDGED AND ACCEPTED

**BELLEVUE GLOBAL LIFE SCIENCES INVESTORS
LLC**

By: Bellevue Capital Management LLC,
Its Manager

By: /s/ Kuk Hyoun Hwang
Name: Kuk Hyoun Hwang
Title: Chief Executive Officer
Email: [**]

**Document and Entity
Information**

Apr. 17, 2024

Document And Entity Information [Line Items]

<u>Amendment Flag</u>	false
<u>Entity Central Index Key</u>	0001840425
<u>Document Type</u>	8-K
<u>Document Period End Date</u>	Apr. 17, 2024
<u>Entity Registrant Name</u>	BELLEVUE LIFE SCIENCES ACQUISITION CORP.
<u>Entity Incorporation State Country Code</u>	DE
<u>Entity File Number</u>	001-41390
<u>Entity Tax Identification Number</u>	84-5052822
<u>Entity Address, Address Line One</u>	10900 NE 4th Street
<u>Entity Address, Address Line Two</u>	Suite 2300
<u>Entity Address, City or Town</u>	Bellevue
<u>Entity Address, State or Province</u>	WA
<u>Entity Address, Postal Zip Code</u>	98004
<u>City Area Code</u>	(425)
<u>Local Phone Number</u>	635-7700
<u>Written Communications</u>	false
<u>Soliciting Material</u>	false
<u>Pre Commencement Tender Offer</u>	false
<u>Pre Commencement Issuer Tender Offer</u>	false
<u>Entity Emerging Growth Company</u>	true
<u>Entity Ex Transition Period</u>	false
<u>Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]</u>	

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Units, each consisting of one share of common stock, one redeemable warrant and one right
<u>Trading Symbol</u>	BLACU
<u>Security Exchange Name</u>	NASDAQ
<u>Common Stock [Member]</u>	

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Common stock, par value \$0.0001 per share
<u>Trading Symbol</u>	BLAC
<u>Security Exchange Name</u>	NASDAQ

Redeemable Warrants Exercisable For Shares Of Common
Stock At An Exercise Price Of 11.50 Per Share 1 [Member]

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share
<u>Trading Symbol</u>	BLACW

Security Exchange Name

NASDAQ

Right To Receive Onetenth 110 Of One Share Of Common
Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title

Right to receive one-tenth (1/10) of one share of
common stock

Trading Symbol

BLACR

Security Exchange Name

NASDAQ

```

{
  "version": "2.2",
  "instance": {
    "id": "828333d8k.htm": {
      "nsPrefix": "blacu",
      "nsURI": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
      "dts": {
        "schemas": {
          "local": {
            "blacu-20240417.xsd"
          },
          "remote": {
            "http://www.abri.org/2003/abri-instance-2003-12-31.xsd",
            "http://www.abri.org/2003/abri-linkbase-2003-12-31.xsd",
            "http://www.abri.org/2003/xl-2003-12-31.xsd",
            "http://www.abri.org/2003/xlink-2003-12-31.xsd",
            "http://www.abri.org/2005/abriid-2005.xsd",
            "http://www.abri.org/2006/ref-2006-02-27.xsd",
            "http://www.abri.org/dtr/type/nonNumeric-2009-12-16.xsd",
            "http://www.abri.org/dtr/type/numeric-2009-12-16.xsd",
            "https://www.abri.org/2020/accessible-nomenclatures-2.0.xsd",
            "https://www.abri.org/dtr/type/2020-01-21/types.xsd",
            "https://www.abri.org/dtr/type/2022-03-31/types.xsd",
            "https://abri.fash.org/act/2023/ata/act-2023.xsd",
            "https://abri.fash.org/act/2023/ata/act-roles-2023.xsd",
            "https://abri.fash.org/act/2023/ata/act-types-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/ata/us-gaap-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/ata/us-roles-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/ata/us-types-2023.xsd",
            "https://abri.sec.gov/country/2023/country-2023.xsd",
            "https://abri.sec.gov/del/2023/del-2023.xsd",
            "https://abri.sec.gov/naics/2023/naics-2023.xsd"
          }
        },
        "definitionLink": {
          "local": {
            "blacu-20240417_def.xml"
          }
        },
        "labelLink": {
          "local": {
            "blacu-20240417_lab.xml"
          }
        },
        "presentationLink": {
          "local": {
            "blacu-20240417_pre.xml"
          }
        },
        "inline": {
          "local": {
            "828333d8k.htm"
          }
        }
      },
      "keyStandard": 24,
      "keyCustom": 0,
      "axisStandard": 1,
      "axisCustom": 0,
      "memberStandard": 1,
      "memberCustom": 3,
      "hidden": {
        "total": 2,
        "http://abri.sec.gov/del/2023": 2
      },
      "contextCount": 5,
      "entityCount": 1,
      "segmentCount": 4,
      "elementCount": 33,
      "unitCount": 0,
      "baseTaxonomies": {
        "http://abri.sec.gov/del/2023": 33
      },
      "report": {
        "xsi": {
          "role": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation",
          "longName": "110010 - Document - Document and Entity Information",
          "shortName": "Document and Entity Information",
          "isDefault": "true",
          "groupType": "Document",
          "subGroupType": "",
          "document": "Cover",
          "order": "1",
          "firstAnchor": {
            "contextRef": "duration_2024-04-17_to_2024-04-17",
            "name": "del:DocumentType",
            "unitRef": null,
            "xsi:nil": "false",
            "lang": "en-US",
            "decimal": null,
            "ancestors": [
              "sgap",
              "p",
              "div",
              "div",
              "body",
              "html"
            ]
          },
          "reportCount": 1,
          "baseRef": "828333d8k.htm",
          "first": true,
          "unique": true
        },
        "uniqueAnchor": {
          "contextRef": "duration_2024-04-17_to_2024-04-17",
          "name": "del:DocumentType",
          "unitRef": null,
          "xsi:nil": "false",
          "lang": "en-US",
          "decimal": null,
          "ancestors": [
            "sgap",
            "p",
            "div",
            "div",
            "body",
            "html"
          ]
        },
        "reportCount": 1,
        "baseRef": "828333d8k.htm",
        "first": true,
        "unique": true
      }
    },
    "tag": {
      "del_AmendmentFlag": {
        "abbrType": "booleanItemType",
        "nsURI": "http://abri.sec.gov/del/2023",
        "localName": "AmendmentFlag",
        "presentation": {
          "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
        },
        "lang": {
          "en-us": {
            "role": {
              "label": "Amendment Flag",
              "targetLabel": "Amendment Flag",
              "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
            }
          }
        },
        "auth_ref": []
      },
      "del_CityAreaCode": {
        "abbrType": "normalizedStringItemType",
        "nsURI": "http://abri.sec.gov/del/2023",
        "localName": "CityAreaCode",
        "presentation": {
          "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
        },
        "lang": {
          "en-us": {
            "role": {
              "label": "City Area Code",
              "targetLabel": "City Area Code",
              "documentation": "Area code of city"
            }
          }
        },
        "auth_ref": []
      },
      "us-gaap_ClassOfStockDomain": {
        "abbrType": "domainItemType",
        "nsURI": "http://fash.org/us-gaap/2023",
        "localName": "ClassOfStockDomain",
        "presentation": {
          "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
        },
        "lang": {
          "en-us": {
            "role": {
              "label": "Class of Stock [Domain]",
              "targetLabel": "Class of Stock [Domain]"
            }
          }
        },
        "auth_ref": []
      },
      "us-gaap_CommonStockMember": {
        "abbrType": "domainItemType",
        "nsURI": "http://fash.org/us-gaap/2023",
        "localName": "CommonStockMember",
        "presentation": {
          "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
        },
        "lang": {
          "en-us": {
            "role": {
              "label": "Common Stock [Member]",
              "targetLabel": "Common Stock [Member]"
            }
          }
        },
        "auth_ref": []
      },
      "del_CoverAbstract": {
        "abbrType": "stringItemType",
        "nsURI": "http://abri.sec.gov/del/2023",
        "localName": "CoverAbstract",
        "lang": {
          "en-us": {
            "role": {

```

```

        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
    }
    },
    "auth_ref": []
},
"del DocumentAndEntityInformationLineItems": {
    "shrType": "RatingItemtype",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
    "localname": "DocumentAndEntityInformationLineItems",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document And Entity Information [line items]",
                "terseLabel": "Document And Entity Information [line items]"
            }
        }
    },
    "auth_ref": []
},
"del DocumentAndEntityInformationTable": {
    "shrType": "RatingItemtype",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
    "localname": "DocumentAndEntityInformationTable",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document And Entity Information [Table]",
                "terseLabel": "Document And Entity Information [Table]"
            }
        }
    },
    "auth_ref": []
},
"del DocumentPeriodEndDate": {
    "shrType": "NascentItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "DocumentPeriodEndDate",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document Period End Date",
                "terseLabel": "Document Period End Date",
                "documentation": "For the EDGAR submission types of Form S-K: the date of the report, the date of the earliest event reported; For the EDGAR submission types of Form S-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
            }
        }
    },
    "auth_ref": []
},
"del DocumentType": {
    "shrType": "SubmissionTypeItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "DocumentType",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document Type",
                "terseLabel": "Document Type",
                "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressAddressLine1": {
    "shrType": "NormalizedStringItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressAddressLine1",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Address Line One",
                "terseLabel": "Entity Address, Address Line One",
                "documentation": "Address line 1 such as Attn, Building Name, Street Name"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressAddressLine2": {
    "shrType": "NormalizedStringItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressAddressLine2",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Address Line Two",
                "terseLabel": "Entity Address, Address Line Two",
                "documentation": "Address line 2 such as Street or Suite number"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressCityOrTown": {
    "shrType": "NormalizedStringItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressCityOrTown",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, City or Town",
                "terseLabel": "Entity Address, City or Town",
                "documentation": "Name of the City or Town"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressPostalZipCode": {
    "shrType": "NormalizedStringItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressPostalZipCode",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Postal Zip Code",
                "terseLabel": "Entity Address, Postal Zip Code",
                "documentation": "Code For the postal or zip code"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressStateOrProvince": {
    "shrType": "NascentItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressStateOrProvince",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, State or Province",
                "terseLabel": "Entity Address, State or Province",
                "documentation": "Name of the state or province."
            }
        }
    },
    "auth_ref": []
},
"del EntityCentralIndexKey": {
    "shrType": "CentralIndexKeyItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityCentralIndexKey",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Central Index Key",
                "terseLabel": "Entity Central Index Key",
                "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
            }
        }
    },
    "auth_ref": [
        "cik"
    ]
},
"del EntityEmergingGrowthCompany": {
    "shrType": "BooleanItemtype",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityEmergingGrowthCompany",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Emerging Growth Company",
                "terseLabel": "Entity Emerging Growth Company",
                "documentation": "Indicate if registrant meets the emerging growth company criteria."
            }
        }
    },
    "auth_ref": []
}

```

```

"p1"
},
{
  "del_EntityExTransitionPeriod": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityExTransitionPeriod",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Ex Transition Period",
          "targetLabel": "Entity Ex Transition Period",
          "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
        }
      }
    },
    "auth_ref": {
      "p3"
    }
  },
  "del_EntityFileNumber": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityFileNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity File Number",
          "targetLabel": "Entity File Number",
          "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_EntityIncorporationStateCountryCode": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityIncorporationStateCountryCode",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Incorporation State Country Code",
          "targetLabel": "Entity Incorporation State Country Code",
          "documentation": "Two-character EDGAR code representing the state or country of incorporation."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_EntityRegistrantName": {
    "shortType": "normalizedStringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityRegistrantName",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Registrant Name",
          "targetLabel": "Entity Registrant Name",
          "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
        }
      }
    },
    "auth_ref": {
      "p1"
    }
  },
  "del_EntityTaxIdentificationNumber": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityTaxIdentificationNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Tax Identification Number",
          "targetLabel": "Entity Tax Identification Number",
          "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
        }
      }
    },
    "auth_ref": {
      "p1"
    }
  },
  "del_LocalPhoneNumber": {
    "shortType": "normalizedStringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "LocalPhoneNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Local Phone Number",
          "targetLabel": "Local Phone Number",
          "documentation": "Local phone number for entity."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_PreCommencementIssuerTenderOffer": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "PreCommencementIssuerTenderOffer",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Pre Commencement Issuer Tender Offer",
          "targetLabel": "Pre Commencement Issuer Tender Offer",
          "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13a-4(c) under the Exchange Act."
        }
      }
    },
    "auth_ref": {
      "p3"
    }
  },
  "del_PreCommencementTenderOffer": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "PreCommencementTenderOffer",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Pre Commencement Tender Offer",
          "targetLabel": "Pre Commencement Tender Offer",
          "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
        }
      }
    },
    "auth_ref": {
      "p4"
    }
  },
  "blacu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": {
    "shortType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
    "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]",
          "targetLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]"
        }
      }
    },
    "auth_ref": {
    }
  },
  "blacu_RightToReceiveOneTenth110OfOneShareOfCommonStockMember": {
    "shortType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
    "localname": "RightToReceiveOneTenth110OfOneShareOfCommonStockMember",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Right To Receive OneTenth 110 Of One Share Of Common Stock [Member]",
          "targetLabel": "Right To Receive OneTenth 110 Of One Share Of Common Stock [Member]"
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_Security12bTitle": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "Security12bTitle",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Security 12b Title",
          "targetLabel": "Security 12b Title",
          "documentation": "Title of a 12(b) registered security."
        }
      }
    }
  }
}

```

```

    },
    "auth_ref": [
        "e0"
    ]
},
"dei_SecurityExchangeName": {
    "xbrlType": "xsd:stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "SecurityExchangeName",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Security Exchange Name",
                "targetLabel": "Security Exchange Name",
                "documentation": "Name of the Exchange on which a security is registered."
            }
        }
    },
    "auth_ref": [
        "e2"
    ]
},
"dei_SolicitingMaterial": {
    "xbrlType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "SolicitingMaterial",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Soliciting Material",
                "targetLabel": "Soliciting Material",
                "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 144+12 under the Exchange Act."
            }
        }
    },
    "auth_ref": [
        "e3"
    ]
},
"us-gaap_StatementClassOfStockAxis": {
    "xbrlType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/us-gaap/2023",
    "localname": "StatementClassOfStockAxis",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Class of Stock [Axis]",
                "targetLabel": "Class of Stock [Axis]"
            }
        }
    },
    "auth_ref": [
        "e4"
    ]
},
"dei_TradingSymbol": {
    "xbrlType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "TradingSymbol",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Trading Symbol",
                "targetLabel": "Trading Symbol",
                "documentation": "Trading symbol of an instrument as listed on an exchange."
            }
        }
    },
    "auth_ref": [
        "e5"
    ]
},
"units_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": {
    "xbrlType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20240417",
    "localname": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]",
                "targetLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]"
            }
        }
    },
    "auth_ref": [
        "e6"
    ]
},
"dei_WrittenCommunications": {
    "xbrlType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "WrittenCommunications",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20240417/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Written Communications",
                "targetLabel": "Written Communications",
                "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
            }
        }
    },
    "auth_ref": [
        "e6"
    ]
}
},
"add_ref": {
    "e0": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "b"
    },
    "e1": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "b-2"
    },
    "e2": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "d1-1"
    },
    "e3": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "13a",
        "subsection": "4c"
    },
    "e4": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "14",
        "subsection": "2b"
    },
    "e5": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "section": "14",
        "number": "240",
        "subsection": "12"
    },
    "e6": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Securities Act",
        "number": "230",
        "section": "425"
    },
    "e7": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Securities Act",
        "number": "13a",
        "section": "8",
        "subsection": "2"
    }
}
}

```